[go: up one dir, main page]

EA200500801A1 - Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции - Google Patents

Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции

Info

Publication number
EA200500801A1
EA200500801A1 EA200500801A EA200500801A EA200500801A1 EA 200500801 A1 EA200500801 A1 EA 200500801A1 EA 200500801 A EA200500801 A EA 200500801A EA 200500801 A EA200500801 A EA 200500801A EA 200500801 A1 EA200500801 A1 EA 200500801A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
sexual dysfunction
morpholine
derivatives
compound
Prior art date
Application number
EA200500801A
Other languages
English (en)
Other versions
EA009589B1 (ru
Inventor
Шарлотт Мойра Норфор Аллертон
Эндрю Дуглас Бакстер
Эндрю Саймон Кук
Дэвид Хепворт
Стефен Квок-Фун Вон
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228787A external-priority patent/GB0228787D0/en
Priority claimed from GB0308460A external-priority patent/GB0308460D0/en
Priority claimed from GB0313606A external-priority patent/GB0313606D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200500801A1 publication Critical patent/EA200500801A1/ru
Publication of EA009589B1 publication Critical patent/EA009589B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее соединение связано с соединениями формулы (I), (Ia) и (Ib), где A выбран из C-X и N, B выбран из C-Y и N, Rвыбран из H и (C-C)алкила, Rвыбран из H и (C-C)алкила, X выбран из H, HO, C(O)NH, NH, Y выбран из H, HO, NH, Br, Cl и F, Z выбран из H, HO, F, CONHи CN; и их фармацевтически приемлемыми солями, сольватами и пролекарствами; при условиях, что для соединения (I), (Ia) или (Ib), когда A представляет собой C-X, B представляет собой C-Y, по меньшей мере один из X, Y и Z должен представлять собой OH; для соединения формулы (I), когда A представляет собой C-X и B представляет собой C-Y, Y представляет собой H, Z представляет собой H, Rпредставляет собой H и Rпредставляет собой H, X не может представлять собой OH; указанные соединения можно применять в качестве агонистов допамина для лечения наряду с другими расстройствами, половой дисфункции.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500801A 2002-12-10 2003-12-02 Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции EA009589B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0228787A GB0228787D0 (en) 2002-12-10 2002-12-10 Morpholine dopamine agonists
GB0308460A GB0308460D0 (en) 2003-04-11 2003-04-11 Morpholine dopamine agonists
GB0313606A GB0313606D0 (en) 2003-06-12 2003-06-12 Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en) 2002-12-10 2003-12-02 Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (2)

Publication Number Publication Date
EA200500801A1 true EA200500801A1 (ru) 2005-12-29
EA009589B1 EA009589B1 (ru) 2008-02-28

Family

ID=32512061

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500801A EA009589B1 (ru) 2002-12-10 2003-12-02 Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции

Country Status (36)

Country Link
EP (1) EP1572214B1 (ru)
JP (3) JP3889775B2 (ru)
KR (1) KR100796102B1 (ru)
AP (1) AP2005003325A0 (ru)
AR (1) AR042339A1 (ru)
AT (1) ATE460938T1 (ru)
AU (1) AU2003302878B2 (ru)
CA (1) CA2508262C (ru)
CO (1) CO5700781A2 (ru)
CR (1) CR7869A (ru)
CY (1) CY1110130T1 (ru)
DE (1) DE60331769D1 (ru)
DK (1) DK1572214T3 (ru)
EA (1) EA009589B1 (ru)
EC (1) ECSP055850A (ru)
ES (1) ES2339767T3 (ru)
GE (1) GEP20074272B (ru)
HN (1) HN2003000401A (ru)
HR (1) HRP20050523A2 (ru)
IS (1) IS7843A (ru)
MA (1) MA27605A1 (ru)
MX (1) MXPA05006151A (ru)
MY (1) MY144338A (ru)
NL (1) NL1024983C2 (ru)
NO (1) NO330143B1 (ru)
NZ (1) NZ540505A (ru)
OA (1) OA13014A (ru)
PA (1) PA8591601A1 (ru)
PE (1) PE20040906A1 (ru)
PL (1) PL377480A1 (ru)
PT (1) PT1572214E (ru)
RS (1) RS51442B (ru)
SI (1) SI1572214T1 (ru)
TW (1) TW200423944A (ru)
UY (1) UY28117A1 (ru)
WO (1) WO2004052372A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677328C1 (ru) * 2013-12-11 2019-01-16 Ф. Хоффманн-Ля Рош Аг Способ получения хиральных 2-арилморфолинов

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4093588B2 (ja) * 2004-05-26 2008-06-04 ファイザー・インク 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
BRPI0511571A (pt) * 2004-05-27 2008-01-02 Pfizer derivados de aminopiridina como agonistas de dopamina d3 seletivos
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
EP2571859B1 (en) 2010-05-21 2015-07-22 Research Triangle Institute 1-phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
WO2011146850A1 (en) * 2010-05-21 2011-11-24 Research Triangle Institute Phenylmorpholines and analogues thereof
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EP3953350A1 (en) 2019-04-12 2022-02-16 The United States of America, as Represented by The Department of Health and Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
CN118684636B (zh) * 2024-05-31 2025-03-11 上海优合贝德医药科技有限公司 一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851311A (en) * 1958-04-02 1960-10-12 Geigy Ag J R Morpholine compounds and their production
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677328C1 (ru) * 2013-12-11 2019-01-16 Ф. Хоффманн-Ля Рош Аг Способ получения хиральных 2-арилморфолинов
US10337039B2 (en) 2013-12-11 2019-07-02 Hoffmann-La Roche Inc. Process for the preparation of chiral 2-aryl morpholines

Also Published As

Publication number Publication date
DE60331769D1 (de) 2010-04-29
MY144338A (en) 2011-08-29
PE20040906A1 (es) 2005-01-24
NZ540505A (en) 2007-02-23
MA27605A1 (fr) 2005-11-01
JP2006232857A (ja) 2006-09-07
AU2003302878B2 (en) 2009-04-23
ATE460938T1 (de) 2010-04-15
ES2339767T3 (es) 2010-05-25
WO2004052372A1 (en) 2004-06-24
AU2003302878A1 (en) 2004-06-30
JP4624341B2 (ja) 2011-02-02
UY28117A1 (es) 2004-07-30
NO20052557L (no) 2005-09-06
PT1572214E (pt) 2010-05-06
EP1572214A1 (en) 2005-09-14
HRP20050523A2 (en) 2005-08-31
CA2508262C (en) 2009-12-01
PL377480A1 (pl) 2006-02-06
KR20050094813A (ko) 2005-09-28
MXPA05006151A (es) 2005-08-26
GEP20074272B (en) 2007-12-25
CA2508262A1 (en) 2004-06-24
PA8591601A1 (es) 2004-12-16
NL1024983A1 (nl) 2004-06-11
HN2003000401A (es) 2004-11-23
JP2007084575A (ja) 2007-04-05
AP2005003325A0 (en) 2005-06-30
AR042339A1 (es) 2005-06-15
SI1572214T1 (sl) 2010-07-30
KR100796102B1 (ko) 2008-01-21
RS51442B (sr) 2011-04-30
EA009589B1 (ru) 2008-02-28
TW200423944A (en) 2004-11-16
CR7869A (es) 2005-07-08
IS7843A (is) 2005-05-12
JP3889775B2 (ja) 2007-03-07
JP2006511599A (ja) 2006-04-06
NL1024983C2 (nl) 2005-02-01
CO5700781A2 (es) 2006-11-30
NO20052557D0 (no) 2005-05-26
CY1110130T1 (el) 2015-01-14
NO330143B1 (no) 2011-02-21
DK1572214T3 (da) 2010-06-07
HK1081850A1 (zh) 2006-05-26
EP1572214B1 (en) 2010-03-17
RS20050445A (sr) 2007-04-10
JP3920908B2 (ja) 2007-05-30
ECSP055850A (es) 2005-09-20
OA13014A (en) 2006-11-10

Similar Documents

Publication Publication Date Title
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
EA200500801A1 (ru) Производные морфолина для применения в качестве агонистов допамина при лечении половой дисфункции
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
EA200500508A1 (ru) Диариловые эфиры в качестве антагониста опиоидного рецептора
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
NZ548196A (en) Aryl aniline derivatives as beta2 adrenergic receptor agonists
ATE440603T1 (de) 8-hydroxychinolinderivate
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2015503625A5 (ru)
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
EA200400994A1 (ru) Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
RU2004133054A (ru) Композиции и способы для борьбы с дисфункциями нижних мочевых путей с использованием агонистов дельта-опиоидных рецепторов
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU